Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220036
Title: Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome
Author: Guijarro Tomas, Francisca
López Guerra, Mònica
Morata, Jordi
Bataller Torralba, Alex
Paz, Sara
Cornet Masana, Josep Maria
Banús Mulet, Antònia
Cuesta Casanovas, Laia
Carbó, José M.
Castaño Díez, Sandra
Jiménez Vicente, Carlos
Cortés Bullich, Albert
Triguero, Ana
Martínez Roca, Alexandra
Esteban, Daniel
Gómez Hernando, Marta
Álamo Moreno, José Ramón
López Oreja, Irene
Garrote i Ordeig, Marta
Risueño, Ruth M.
Tonda, Raúl
Gut, Ivo G.
Colomer, Dolors
Díaz Beyà, Marina
Esteve Reyner, Jordi
Keywords: Malalties hematològiques
Càncer
Leucèmia mieloide
Genètica humana
Hematologic diseases
Cancer
Myeloid leukemia
Human genetics
Issue Date: 10-Oct-2023
Publisher: American Society of Hematology
Abstract: Germ line predisposition in acute myeloid leukemia (AML) has gained attention in recent years because of a nonnegligible frequency and an impact on management of patients and their relatives. Risk alleles for AML development may be present in patients without a clinical suspicion of hereditary hematologic malignancy syndrome. In this study we investigated the presence of germ line variants (GVs) in 288 genes related to cancer predisposition in 47 patients with available paired, tumor-normal material, namely bone marrow stroma cells (n = 29), postremission bone marrow (n = 17), and saliva (n = 1). These patients correspond to 2 broad AML categories with heterogeneous genetic background (AML myelodysplasia related and AML defined by differentiation) and none of them had phenotypic abnormalities, previous history of cytopenia, or strong cancer aggregation. We found 11 pathogenic or likely pathogenic variants, 6 affecting genes related to autosomal dominant cancer predisposition syndromes (ATM, DDX41, and CHEK2) and 5 related to autosomal recessive bone marrow failure syndromes (FANCA, FANCM, SBDS, DNAJC21, and CSF3R). We did not find differences in clinical characteristics nor outcome between carriers of GVs vs noncarriers. Further studies in unselected AML cohorts are needed to determine GV incidence and penetrance and, in particular, to clarify the role of ATM nonsense mutations in AML predisposition.
Note: Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2023009742
It is part of: Blood Advances, 2023, vol. 7, num.19, p. 5799-5811
URI: https://hdl.handle.net/2445/220036
Related resource: https://doi.org/10.1182/bloodadvances.2023009742
ISSN: 2473-9529
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
891617.pdf631.95 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.